FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904901116> ?p ?o ?g. }

• W2904901116 endingPage "2598" @default.
• W2904901116 startingPage "2598" @default.
• W2904901116 abstract "Abstract Current precision medicine approaches typically target a single genetic mutation. However, adult acute myeloid leukemia (AML) is difficult to treat due to its genetic complexity. Approximately 30 somatic mutations have been found to be recurrent, with an average of 5-15 mutations present per patient (Cancer Genome Atlas 2013). Therefore, combinatorial genetic approaches have the power to uncover novel gene targets that can be used to tailor therapies to an individual's unique mutational spectrum. Mutations in NPM1 commonly occur in in AML. Approximately 25-30% of patients harbor a specific variant of the NPM1 mutation referred to as NPM1cA, which results in mislocalization of the Npm1 protein from the nucleus to the cytoplasm (Cancer Genome Atlas 2013; Falini 2005). While NPM1cA is considered to be a driver of AML development, mice with this mutation develop AML with a long latency (18 months) and with incomplete penetrance (Vassiliou 2011). In addition, those mice that do develop AML acquire additional genetic mutations, suggesting that NPM1cA cooperates with serially acquired mutations to drive AML development (Dovey 2017). It was recently discovered that mutations in the cohesin complex (consisting of the genes STAG2, SMC1A, SMC3, and RAD21) are also common in AML, with mutation in any of the four components resulting in haploinsufficiency (Cancer Genome Atlas 2013). Cohesin haploinsufficiency is enriched in patients with NPM1 mutations. Although cohesin mutations alone are insufficient to generate AML in mice (Viny 2015), they do result in increased hematopoietic stem and progenitor cell (HSPC) self-renewal (Mazumdar 2015; Fisher 2017). As the cohesin complex has known roles in chromosomal organization and the regulation of gene expression, we hypothesized that cohesin mutations would cooperate with NPM1cA to uniquely alter gene expression, resulting in AML. We crossed inducible NPM1cAflox/+ and SMC3flox/+ mouse models to examine this genetic interaction. Our current data show that the double mutant mice develop AML with increased penetrance compared with the Npm1cA/+ mice alone, with a trend toward decreased latency. The double mutant HSPCs also exhibit increased self-renewal in vitro compared to the Npm1cA/+ or SmcΔ/+ single mutants. To examine changes in gene expression, we performed RNA sequencing on lineage-depleted bone marrow in 3 mice from each genotype (WT, Npm1cA/+, Smc3Δ/+, and double) 4 weeks post excision. Consistent with our hypothesis, additive changes in gene expression were not observed. Instead, a unique set of genes were found to be deregulated in Npm1cA/+; Smc3Δ/+ marrow. In an effort to specifically target Npm1cA/+; Smc3Δ/+ mutant AML, we screened our list of uniquely-affected genes for those associated with AML. We found DOCK1 to be overexpressed in the double, but not Npm1cA/+ single, cells. High expression of this gene has been correlated with decreased overall and disease-free survival in AML patients (Lee 2017). To determine if DOCK1 contributes to the enhanced cell growth observed in vitro in our leukemic lines, we used an inhibitor that targets Dock1. This inhibitor induced apoptosis in our double leukemic cell lines but was less effective in our NPM1 single mutant or WT cells. Additionally, no effect was observed with a genetically unrelated AML line, MLL-AF9. Similarly, shRNA-mediated knockdown of Dock1 resulted in decreased cell viability in Npm1cA/+; Smc3Δ/+ leukemic lines but not in Npm1cA/+ only lines. We thus hypothesize that Dock1 represents a unique target for the treatment of patients harboring the Npm1/Cohesin mutational combination. Our results provide validity to the concept that combinatorial genetics can be used to target the unique genetic landscape of an individual patient. Future studies will focus on the impact of Dock1 inhibition in human Npm1/Cohesion mutated AML cell lines. Disclosures Vassiliou: KYMAB: Consultancy, Equity Ownership; Celgene: Research Funding. Levine:Isoplexis: Equity Ownership; Epizyme: Patents & Royalties; Imago: Equity Ownership; Loxo: Consultancy, Equity Ownership; Janssen: Consultancy, Honoraria; Gilead: Honoraria; Prelude: Research Funding; Novartis: Consultancy; Celgene: Consultancy, Research Funding; Roche: Consultancy, Research Funding; C4 Therapeutics: Equity Ownership; Qiagen: Equity Ownership, Membership on an entity's Board of Directors or advisory committees." @default.
• W2904901116 created "2018-12-22" @default.
• W2904901116 creator A5025660159 @default.
• W2904901116 creator A5031833096 @default.
• W2904901116 creator A5036613947 @default.
• W2904901116 creator A5044518913 @default.
• W2904901116 creator A5060946133 @default.
• W2904901116 creator A5070692514 @default.
• W2904901116 creator A5081020822 @default.
• W2904901116 creator A5091241671 @default.
• W2904901116 date "2018-11-29" @default.
• W2904901116 modified "2023-09-27" @default.
• W2904901116 title "Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML" @default.
• W2904901116 doi "https://doi.org/10.1182/blood-2018-99-113011" @default.
• W2904901116 hasPublicationYear "2018" @default.
• W2904901116 type Work @default.
• W2904901116 sameAs 2904901116 @default.
• W2904901116 citedByCount "0" @default.
• W2904901116 crossrefType "journal-article" @default.
• W2904901116 hasAuthorship W2904901116A5025660159 @default.
• W2904901116 hasAuthorship W2904901116A5031833096 @default.
• W2904901116 hasAuthorship W2904901116A5036613947 @default.
• W2904901116 hasAuthorship W2904901116A5044518913 @default.
• W2904901116 hasAuthorship W2904901116A5060946133 @default.
• W2904901116 hasAuthorship W2904901116A5070692514 @default.
• W2904901116 hasAuthorship W2904901116A5081020822 @default.
• W2904901116 hasAuthorship W2904901116A5091241671 @default.
• W2904901116 hasConcept C104317684 @default.
• W2904901116 hasConcept C115821613 @default.
• W2904901116 hasConcept C127716648 @default.
• W2904901116 hasConcept C2483381 @default.
• W2904901116 hasConcept C2778729363 @default.
• W2904901116 hasConcept C30481170 @default.
• W2904901116 hasConcept C501734568 @default.
• W2904901116 hasConcept C502942594 @default.
• W2904901116 hasConcept C53226629 @default.
• W2904901116 hasConcept C54355233 @default.
• W2904901116 hasConcept C68838962 @default.
• W2904901116 hasConcept C83640560 @default.
• W2904901116 hasConcept C86803240 @default.
• W2904901116 hasConceptScore W2904901116C104317684 @default.
• W2904901116 hasConceptScore W2904901116C115821613 @default.
• W2904901116 hasConceptScore W2904901116C127716648 @default.
• W2904901116 hasConceptScore W2904901116C2483381 @default.
• W2904901116 hasConceptScore W2904901116C2778729363 @default.
• W2904901116 hasConceptScore W2904901116C30481170 @default.
• W2904901116 hasConceptScore W2904901116C501734568 @default.
• W2904901116 hasConceptScore W2904901116C502942594 @default.
• W2904901116 hasConceptScore W2904901116C53226629 @default.
• W2904901116 hasConceptScore W2904901116C54355233 @default.
• W2904901116 hasConceptScore W2904901116C68838962 @default.
• W2904901116 hasConceptScore W2904901116C83640560 @default.
• W2904901116 hasConceptScore W2904901116C86803240 @default.
• W2904901116 hasIssue "Supplement 1" @default.
• W2904901116 hasLocation W29049011161 @default.
• W2904901116 hasOpenAccess W2904901116 @default.
• W2904901116 hasPrimaryLocation W29049011161 @default.
• W2904901116 hasRelatedWork W1898985322 @default.
• W2904901116 hasRelatedWork W1981424553 @default.
• W2904901116 hasRelatedWork W2043199743 @default.
• W2904901116 hasRelatedWork W2141307855 @default.
• W2904901116 hasRelatedWork W2351781254 @default.
• W2904901116 hasRelatedWork W2438494957 @default.
• W2904901116 hasRelatedWork W2604181045 @default.
• W2904901116 hasRelatedWork W3009206022 @default.
• W2904901116 hasRelatedWork W3032161284 @default.
• W2904901116 hasRelatedWork W3209716189 @default.
• W2904901116 hasVolume "132" @default.
• W2904901116 isParatext "false" @default.
• W2904901116 isRetracted "false" @default.
• W2904901116 magId "2904901116" @default.
• W2904901116 workType "article" @default.